Mochi + Aequita Files: Pharmacy Workers from Home Depot?

When a Whistleblower Speaks, Patients Should Listen

Original posted at obesity.news/ on Oct 26, 2025

This whole story adds to my worry about the broader conversation of patient safety in compounding, especially as more and more actors flow into this space. At the heart of it all is one question: when do profitability and brand reputation begin to outweigh patient safety and ethics?

A newly surfaced Washington State Department of Health investigation (Case #2024-17788CF) details a whistleblower complaint alleging that Aequita Pharmacy, affiliated with Mochi Health, allowed unlicensed workers to handle and ship GLP-1 medications, used mislabeled raw materials, and even experimented with sterilization techniques on patient drugs.

These are allegations, not conclusions, but they come straight from official state records obtained through a public request by

Leefitsin, an attorney and GLP-1 advocate (and longtime friend of OTP) who’s been fighting for transparency in this space since day one.

I thought it was important to have Lee on and talk about his interpretation of all of this, Lee and I walk through the report line by line. We’re not speaking as prosecutors or regulators, we’re patients and advocates who believe that when people are injecting medication into their bodies, they deserve to know who’s making it, what’s in it, and who’s accountable.

🎥 Watch the full video below:

What do you think about this story? What is the most shocking allegation in your opinion, and why? Sound off below!

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe